Case 12: extra and HIV Flashcards

1
Q

Shingles vaccine

A
  • Offered to all patients aged 70-79 years
  • is live-attenuated and given sub-cutaneously
  • Don’t give if immunocompromised
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Shingles progression

A
  • Prodrome: acute neuralgia (tingling, burning pain with enlarged lymph nodes(typically 2-3 days)
  • Infectious: rash (affects single dermatome in a band like distribution) rarely crosses the midline, pain where the rash is (7-10 days)
  • Resolution: vesicles crust other and take a month to disappear
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Chicken pox pathophysiology

A
  • spread via the respiratory route
  • can be caught from someone with shingles
  • infectivity = 4 days before rash, until 5 days after the rash first appeared*
  • incubation period = 10-21 days
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Chicken pox clinical features

A
  • Fever initially
  • itchy, rash starting on head/trunk before spreading. Initially macular then papular then vesicular
  • Generalised pruritic rash
  • Macular -> Papular -> Vesicular -> Crusted
  • systemic upset is usually mild
  • Usually mild in healthy children, more severe if immunocompromised, neonates and adults
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Management of chicken pox

A
  • Calamine lotion
  • School exclusion:Advise that the most infectious period is 1–2 days before the rash appears, but infectivity continues until all the lesions are dry and have crusted over (usually about 5 days after the onset of the rash).
  • Immunocompromised patients and newborns with peripartum exposure should receivevaricella zosterimmunoglobulin (VZIG). If chickenpox develops then IV aciclovir should be considered
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Infective endocarditis

A

An infection of the endocardial surface of the heart including one or more of the valves. Rare and life threatening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

IE pathophysiology

A

Turbulent blood flow causes damage to the smooth endothelium, causes accumulation of platelets, fibrin, leukocytes which can be infected by circulating microorganisms forming a vegetation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Risk factors for IE

A
  • Age >60years, Male
  • Intravenous drug use particularly increased risk of right sided IE
  • Intravascular lines
  • Chronic haemodialysis (usually have a fistula or a long-term haemodialysis catheter which can become infected)
  • Immunosuppression
  • Recentdental or surgical procedure
  • Cardiac factors: history of prior IE, prosthetic heart valve, cardiac devices (pace maker) structural heart disease (valvular or congenital)
  • Rheumatic heart disease with mitral valve affected
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Causes of IE

A
  • Staphylococcusaureus (most common cause of IE, associated with IVDU)
  • Viridians group streptococcus(more prevalent among some older populations and community-acquired IE, recent dental extraction)
  • Enterococci (3rd highest cause, linked to health care contact and recurrent UTI’s)
  • Streptococci bovis(high association with bowel cancer)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Unusual causes of IE

A
  • Coxiella burnetii(the causative agent of Q fever, associated with abattoirs / livestock)
  • Bartonella spp (associated with alcoholism or homelessness)
  • Brucella spp (travel to the Middle East or the Mediterranean or consumption of unpasteurized dairy products)
  • Bartonella henselae (contact with cats )
  • Aspergillus spp. (extensive health care contact in a patient with a prosthetic valve
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Clinical manifestations of IE

A
  • Fever- with chills, anorexia and weight loss
  • Non-specific: malaise, arthralgia, night sweats and abdominal pain
  • Heart murmurs: usually in left IE
  • Cutaneous manifestations: Petechiae and splinter haemorrhages
  • Specific to IE: Janeway lesions (non-tender), Osler nodes (tender), Roth spots (haemorrhagic retinal lesions with a pale centre)
  • Long standing disease: finger clubbing and Splenomegaly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Pulmonary septic emboli

A

Is the most common presentation of isolated right-sided IE (10% of all cases of IE). Presents with a cough, dyspnoea, haemoptysis or pleuritic chest pain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Investigations or IE

A
  • Blood cultures: 3 samples from different sites with a gap of 1-6hr. Must be taken before antibiotics. 2 sets within 1hr if septic and starting abx. Dont wait till temperature spike.
  • Bloods: FBC, CRP, ESR, U&E, LFT
  • Transthoracic echocardiogram (TTE): first line investigation
  • Transoesophageal echocardiogram (TOE): Do if TTE is negative
  • ECG
  • CXR: to look for pulmonary septic emboli, congestive heart failure or ay abscess’s
  • CT scan (thoracic, abdominal and pelvis): for metastatic infections
  • Special investigations for prosthetic heart valves: 18F-FDG PET/CT, SPECT-CT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Modified Duke criteria

A
  • Used to diagnose infective endocarditis based on either Clinical or Pathological criteria
  • Clinical criteria: Requires One major plus three minor criteria or five minor criteria
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

DUKE’s major criteria

A
  • Persistently positive blood cultures (Of organisms which cause IE) , cultures must be separated in time
  • Imaging findings (echocardiogram) of endocardial involvement : vegetation, abscess, Prosthetic valve dehiscence, new regurgitation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Duke’s pathological criteria

A
  • Microorganisms demonstrated by culture or histology of a vegetation or emboli
  • Vegetation or abscess confirmed by histology to be active endocarditis
  • Both require surgical intervention: either culture of histology
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Duke’s minor criteria

A
  • Predisposition (heart disease) or IVDU
  • Fever >38
  • Vascular phenomena (Janeway lesions)
  • Immunological phenomena (Osler nodes, Roth spots)
  • Microbiological phenomena
  • PCR
  • Echocardiographic findings
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Managing IE

A
  • IV Antibiotics (i.e. amoxicillin and optional gentamicin): can delay based on blood culture results if stable
  • HACEK organisms can be treated with Ceftriaxone
  • Antibiotics are given for 4 weeks in native heart valves and 6 weeks in prosthetic
  • Remove source of infection: i.e. intravascular catheter, intracardiac device, arteriovenous fistula. May need dental evaluation
  • Colonoscopy: when group D streptococci is found on culture
  • Valve surgery
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Different antibiotics for IE

A
  • If stable wait for blood culture results
  • Native valve: Amoxicillin with optional gentamicin
  • Native valve with sepsis: Vancomycin and gentamycin
  • Prosthetic valve: Vancomycin, Gentamycin and Rifampicin
  • HACEK (gram negative): Ceftriaxone or Amoxicillin, Gentamicin for first 2 weeks, alternative is Ciprofloxacin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

When is valve surgery indicated

A
  • IE-associated valvular regurgitation/dysfunction
  • Associated complications i.e. septic emboli
  • Heart failure
  • Intracardiac abscess or large vegetations (>10mm)
  • Infections not responding to antibiotics (fungal or antimicrobial resistant) 7 day cut off
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

IE- Echo follow up

A
  • If concerned about complications i.e. new murmur or embolic events
  • Following antibiotic therapy as complete resolution of vegetation is uncommon so need to establish new baseline
  • Remain under follow up for 1 year: monitor development of heart failure, end of treatment TTE, discuss recurrence
22
Q

IE: complications

A
  • Cardiac: congestive heart failure, pericarditis
  • Septic pulmonary emboli
  • Neurological: embolic stroke, intracerebral haemorrhage
  • Renal: renal infarction, abscess, glomerulonephritis
  • Musculoskeletal: vertebral osteomyelitis, septic arthritis, psoas abscess
  • Splenic infarct or abscess
  • Systemic: rheumatoid factor may be raised
  • Death: quarter die even with treatment. Without treatment all die.
  • Left sided IE: emboli travel around the body except for the lung which is from the right
23
Q

IE: factors associated with worse prognosis

A
  • Heart failure, renal failure, Brain haemorrhage, septic shock
  • Larger vegetation size
  • Microbiology (S.aureus, Fungi, Non-HACEK gram negative bacilli)
  • Perivalvular abscess, severe valvular dysfunction
  • Poor surgical candidate (early valve surgery confers a lower mortality risk)
24
Q

HIV

A
  • A retrovirus which targets CD4+ T lymphocyte, Macrophages and dendritic cells
  • Transmitted: sexual contact, IV drug use, and vertical
  • HIV-1: more prevalent and aggressive
  • HIV-2: less pathogenic and found in West Africa
25
Q

HIV structure

A
  • Contains single stranded RNA (two copies contained within the nuclear capsid)
  • Nuclear capsid is made of viral p24 protein: target for serological tests (as well as HIV envelope protein)
  • Cell membrane is made from a lipid derived from host T cell
  • Contains enzymes: Protease, Integrase, Reverse Transcriptase
  • Glycoprotein complex consisting of gp120 and three gp41 anchoring stems (anchor the complex to the lipid membrane)- allow HIV to attach to other cells (CD4 lymphocyte and Macrophages)
26
Q

HIV: risk factors

A
  • Unprotected sex
  • Multiple sexual partners
  • IV drug use
  • Blood transfusion
  • Mother to child transmission
  • Occupational exposure
  • High risk sexual behaviour: anal sex, prostitutes
  • Sub-Saharan Africa
  • Others STI’s
27
Q

How HIV enters the cell

A
  • HIV can infect CD4 T cells, macrophages and dendritic cells
  • gp120 binds to CD4 and CXCR4 on T cells and CD4 and CCR5 on macrophages and releases their capsid into the host cell
  • HIV viral envelope fuses with the target cell membrane and releases their viral contents into the cell
  • mutations in CCR5 can give immunity to HIV
28
Q

Mechanism of HIV integration

A
  • After entering a cell reverse transcriptase creates dsDNA from the RNA (by reverse transcriptase enzyme) for integration into the host cell’s genome by the viral integrase enzyme
  • Drug resistance can develop in the reverse transcription step due to mutations
  • Viral DNA can be dormant for many years
  • When activated can reduce functionality and number of CD4 cells causing immunosuppression.
29
Q

Mechanism of HIV replication

A
  • viral DNA is transcribed back into RNA by host cell
  • RNA is transported from the nucleus to the cytoplasm
  • viral RNA is used to make viral proteins by the viral protease enzyme
  • viral proteins form a new immature HIV which can infect other cells. Envelope is formed from lipid components of the host cell
  • protease allows the virus to mature
30
Q

HIV seroconversion

A
  • Occurs 3-12 weeks post infection
  • Increased symptoms associated with worse prognosis
  • Features: sore throat, lymphadenopathy, malaise, myalgia, arthralgia, diarrhoea, diffuse maculopapular rash
  • A glandular fever type picture
31
Q

How the CD4 count changes

A
  • Initially there is a transient decrease in CD4 during the seroconversion
  • Afterwards the CD4 count recovers but not fully
  • CD4 count is stable for 5 years then slowly declines
  • Initial increase in HIV RNA and p24 antigen which then decline though not fully
32
Q

Diagnosing HIV

A
  • ELISA for HIV antibodies and p24 anitgens: Negative test within 45 days of exposure is unreliable. First line
  • Point of care (POC) tests for HIV antibodies give results within minutes unreliable first 90 days. Get results quickly need to confirm with labs
  • HIV RNA: for screening blood donors and in neonatal, indicates viral load
  • At home testing kits: self sampling kits, point of care kits
33
Q

CD4 level

A
  • 500-1200 cells/mmis the normal range
  • Under 200 cells/mmputs the patient at high risk of opportunistic infections
  • Flow cytometry detect levels of CD4 lymphocytes
  • Viral load is detected by PCR
34
Q

HIV management

A
  • Highly active anti-retroviral therapy (HAART): Two NRTI’s (i.e. Tenofovir plus Emtricitabine) and a PI or a NNRTI.
  • Alternative combination of NRTI’s: ABC (abacavir) and 3TC (lamivudine)
  • Summary: 2 NRTI’s + a 3rd drug from a different class
35
Q

Outcomes of HIV treatment

A
  • CD4 count and viral count can recover fully with medication meaning they can have a normal life expectancy
  • Start medication from diagnosis
  • CD4 count may remain low, if <200 need long term prophylaxis
  • Viral load is how you monitor treatment progression
  • Changes to treatment should only be made by a specialist
  • Need combined therapies to prevent development of resistance (cant acquire enough mutations)
36
Q

HIV: Entry inhibitors and examples of Integrase inhibitors

A

Entry inhibitors
- maraviroc, enfuvirtide
- prevent HIV-1 from entering and infecting immune cells

Integrase inhibitors examples: raltegravir, elvitegravir, dolutegravir

37
Q

Nucleoside analogue reverse transcriptase inhibitors (NRTI)

A
  • examples: zidovudine (AZT), abacavir, emtricitabine, didanosine, tenofovir
  • general NRTI side-effects: peripheral neuropathy
  • tenofovir: Adverse effects include renal impairment and ostesoporosis
  • zidovudine: anaemia, myopathy, black nails
  • MoA: mimics nucleotides that are used to form viral DNA
38
Q

HIV: Non-nulceoside reverse transcriptase inhibitors (NNRTI)

A
  • examples: nevirapine, efavirenz
  • side-effects: P450 enzyme interaction (nevirapine induces), rashes
  • MoA: bind directly to reverse transcriptase preventing it from adding new nucleotides to the growing DNA chains
39
Q

HIV: Protease inhibitors (PI)

A
  • examples: indinavir, nelfinavir, ritonavir
  • side-effects: diabetes, buffalo hump, central obesity, P450 enzyme inhibition
  • indinavir: renal stones, asymptomatic hyperbilirubinaemia
  • MoA: prevents the breakup of new viral proteins so the building blocks for new viruses are not available
40
Q

General side effects of anti-retroviral therapy

A
  • D/V
  • steatosis/ hepatitis
  • mild rash
  • lipodystrophy (fat reduction peripherally but gain centrally)
  • diabetes and dyslipidaemia
41
Q

HIV additional management

A
  • Prophylactic co-trimoxazole: given if CD4 <200 to protect against PCP
  • Yearly cervical smears
  • Vaccinations against influenza, pneumococcal, HPV and hepatitis A and B. Avoid live vaccines
42
Q

HIV: giving birth (viral load)

A
  • <50: normal vaginal delivery
  • > 50: consider a pre-labour caesarean section
  • > 400: pre-labour caesarian is recommended
  • > 1000 or unknown: give IV zidovudine as an infusion during labour
43
Q

HIV prophylaxis for baby: depending on mothers viral load and breast feeding

A
  • Low-risk babies (mother’s viral load is under 50 copies per ml) are givenzidovudinefor 2-4 weeks
  • High-risk babies are givenzidovudine,lamivudineandnevirapinefor four weeks
  • Breast feeding: advised not but can if viral load undetectable
44
Q

HIV prophylaxis

A
  • PEP must be commenced within 72 hours of exposure
  • PEP involves a combination ofART therapy. The current regime isemtricitabine/tenofovir(Truvada) andraltegravirfor 28 days.
  • Pre-exposure prophylaxis(PrEP) is also available to take before exposure. The usual choice isemtricitabine/tenofovir(Truvada).
45
Q

AID’s defining illness

A
  • When CD4 count drops to a level allowing for opportunistic infections
  • Examples: Kaposi sarcoma, PCP, CMV, Candidiasis (oesophageal or bronchial), lymphoma, tuberculosis
46
Q

HIV: complications of CD4 >500

A
  • GBS
  • Chronic demyelinating neuropathy
  • Idiopathic thrombocytopaenia
  • Reifter’s syndrome
  • Polymyositis
  • Sjogrens syndrome
  • Bell’s palsy
47
Q

HIV: complications of CD4 350-500

A
  • cutaneous manifestations e.g. folliculitis
  • psoriasis/ eczema that is refractory to treatment
  • shingles that is recurrent or multi-dermatomal
  • bacterial pneumonia
  • GBS or other demyelinating neuropathies
48
Q

Complications of HIV: CD4 200-350

A
  • Oral thrush: secondary to Candida albicans
  • Hairy Leukoplakia: secondary to EBV
  • diarrhoea illness due to parasitic infections such as cryptosporidiosis
  • pulmonary TB
49
Q

Complications of HIV: CD4 count 100-200

A
  • Cryptosporidiosis
  • Cerebral toxoplasmosis
  • Progressive multifocal leukoencephalopathy: secondary to JC virus
  • Pneumocystis jirovecii pneumonia
  • Kaposi sarcoma secondary to HHV-8
  • HIV dementia
50
Q

Complications of HIV: CD4 count 50-100

A
  • Aspergillosis: secondary to Aspergillus fumigatus
  • Oesophageal candidiasis: secondary to Candida albicans
  • Cryptococcal meningitis
  • Primary CNS lymphoma: secondary to EBV